Trials / Completed
CompletedNCT02619929
Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria
Assessment of Initial Oral Vinorelbine Dosing Schedules Used for the Treatment of Advanced Non-small-cell Lung Cancer and Metastatic Breast Cancer in Clinical Routine in Germany and Austria (StepUp)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 108 (actual)
- Sponsor
- Pierre Fabre Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this non-interventional study is to assess oral vinorelbine dose schedules (initial dose, dose increase/maintenance/reduction) applied during the initial 8 weeks of treatment under routine conditions in Germany together with the underlying reasons for the respective chosen schedules.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vinorelbine oral |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2015-12-02
- Last updated
- 2018-08-29
Locations
56 sites across 2 countries: Austria, Germany
Source: ClinicalTrials.gov record NCT02619929. Inclusion in this directory is not an endorsement.